Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced today that it will take part in an unplugged fireside discussion at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY, Dec 3-5, 2024.
波士頓，2024年11月25日（全球新聞通訊）-- Cue Biopharma, Inc.（納斯達克：CUE），一家臨牀階段的生物製藥公司，正在開發一種新型的治療性生物製品，以選擇性地參與和調節針對特定疾病的T細胞，用於治療癌症和自身免疫性疾病，今天宣佈將參加2024年12月3日至5日在紐約舉行的派傑投資第36屆年度醫療會議中的一次非正式的爐邊討論。
During the fireside discussion, Cue Biopharma will provide an overview highlighting recent clinical and preclinical program updates as well as strategic business and partnering model objectives.
在爐邊討論中，Cue Biopharma將提供一個概述，重點介紹最近的臨牀和臨牀前項目更新以及戰略業務和合作模型目標。
Presentation Details
Date and Time: Wednesday, December 4, 2024, from 9 a.m. EST – 9:25 a.m. EST
Webcast Link:
Presenter: Daniel Passeri, M.Sc., J.D., chief executive officer, Cue Biopharma
演示細節
日期和時間：2024年12月4日，星期三，上午9點（東部標準時間）至上午9:25（東部標準時間）
網絡直播鏈接：
Presenter: Daniel Passeri萬.Sc., J.D., chief executive officer, Cue Biopharma
A live and archived webcast of the fireside discussion will be available on the Events page in the Investors and Media section of the Company's website at . The webcast will be archived for 30 days.
會議討論的直播和存檔網絡廣播將在公司網站的投資者和媒體部分的活動頁面上提供。該網絡廣播將存檔30天。
About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body. The company's proprietary platform, Immuno-STAT (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body's intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.
關於Cue Biopharma
Cue Biopharma是一家臨牀階段的生物製藥公司，正在開發一種新型的可注射生物製品，旨在在患者體內選擇性地激活和調節特定疾病的t細胞。該公司的專有平台Immuno-STAt（選擇性靶向和改變t細胞）和生物製品旨在通過選擇性調節特定疾病的t細胞來利用人體內在免疫系統的治癒潛力，而無需廣泛的系統性免疫調節的副作用。
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
公司總部位於馬薩諸塞州波士頓，由一個經驗豐富的管理團隊和獨立的董事會領導，他們在免疫學和免疫腫瘤學方面擁有豐富的專長，以及蛋白質生物製品的設計和臨牀開發方面的深厚經驗。
For more information please visit and follow us on X and LinkedIn.
欲了解更多信息，請訪問並關注我們的X和LinkedIn。
Investor Contact
Marie Campinell
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com
投資者聯繫
瑪麗·坎皮內爾
高級董事，企業通信
Cue Biopharma, Inc.
mcampinell@cuebio.com
Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com
媒體聯繫
喬納森·帕帕斯
通信
jpappas@lifescicomms.com
